Johnson Fistel Begins Investigation into ADMA Biologics, Inc. Following a Significant Drop in the Company’s Stock

SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP is investigating whether ADMA Biologics, Inc. (NASDAQ: ADMA) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

What if I purchased ADMA Biologics securities? If you purchased securities and suffered losses on your investment, join our investigation now:

Click Here to Join the Investigation

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to you.

What is Johnson Fistel investigating? ADMA Biologics is a comprehensive commercial biopharmaceutical company specializing in the manufacturing, marketing, and development of specialty biologics aimed at treating immunodeficient patients and others at risk for certain infectious diseases. On October 9, 2024, ADMA Biologics announced the unexpected resignation of its independent outside auditor, CohnReznick LLP. This announcement led to a significant drop in ADMA Biologics’ stock price, which fell by over 20% during trading on October 10, 2024.

What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistel, LLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
jimb@johnsonfistel.com or fjohnson@johnsonfistel.com